




Instance: composition-en-aefacad9a6795a89d3df82b1bc20e9aa
InstanceOf: CompositionUvEpi
Title: "Composition for plerixafor Package Leaflet"
Description:  "Composition for plerixafor Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpac7a0eeae12e9d2b6aed180d539c6255)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - plerixafor"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Plerixafor Accord is and what it is used for </li>
<li>What you need to know before you use Plerixafor Accord </li>
<li>How to use Plerixafor Accord </li>
<li>Possible side effects </li>
<li>How to store Plerixafor Accord </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What plerixafor is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What plerixafor is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Plerixafor Accord contains the active substance plerixafor which blocks a protein on the surface of 
blood stem cells. This protein  ties  blood stem cells to the bone marrow. Plerixafor improves the 
release of stem cells into the blood stream (mobilisation). The stem cells can then be collected by a 
machine that separates blood constituents (apheresis machine), and subsequently frozen and stored 
until your transplant. </p>
<p>If mobilisation is poor, Plerixafor Accord is used to help collect blood stem cells from the patient, for 
collection, storage and reintroduction (transplantation), </p>
<p>In adults who have lymphoma (a cancer of the white blood cells) or multiple myeloma (a cancer 
that affects plasma cells in the bone marrow). </p>
<p>In children age 1 to less than 18 years of age with lymphoma or solid tumours. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take plerixafor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take plerixafor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Plerixafor Accord 
- if you are allergic to plerixafor or any of the other ingredients of this medicine (listed in section 
6). </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist or nurse before using Plerixafor Accord. </p>
<p>Tell your doctor:</p>
<ul>
<li>if you have or have had any heart problems. </li>
<li>if you have kidney problems. Your doctor may adjust the dose. </li>
<li>if you have high white blood cell counts. </li>
<li>if you have low platelet counts. </li>
<li>if you have a history of feeling faint or lightheaded on standing or sitting or have fainted before 
upon injections. </li>
</ul>
<p>Your doctor may perform regular blood tests to monitor your blood cell count. </p>
<p>It is not recommended to use Plerixafor Accord for stem cell mobilisation if you have leukaemia (a 
cancer of the blood or bone marrow). </p>
<p>Other medicines and Plerixafor Accord 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Pregnancy and breast-feeding 
You should not use Plerixafor Accord if you are pregnant, since there is no experience with Plerixafor 
Accord in pregnant women. It is important to tell your doctor if you are, think you may be or are 
planning to become pregnant. It is recommended to use contraception if you are of child-bearing age. </p>
<p>You should not breast-feed if you are using Plerixafor Accord, since it is not known if Plerixafor 
Accord is excreted in human milk. </p>
<p>Driving and using machines 
Plerixafor Accord may cause dizziness and fatigue. Therefore, you should avoid driving if you feel 
dizzy, tired or unwell. </p>
<p>Plerixafor Accord contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially  sodium-
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take plerixafor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take plerixafor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Your medicine will be injected by a doctor or a nurse. </p>
<p>You will first receive G-CSF, then you will be given Plerixafor Accord 
Mobilisation will be started by first giving you another medicine called G-CSF (granulocyte-colony 
stimulating factor). G-CSF will help Plerixafor Accord to work properly in your body. If you want to 
know more about G-CSF ask your doctor and read the corresponding package leaflet. </p>
<p>How much Plerixafor Accord is given? 
The recommended adult dose is either a 20 mg (fixed dose) or 0.24 mg/kg body weight/day. 
The recommended dose for children, 1 to less than 18 years of age is 0.24 mg/kg of body weight/day. </p>
<p>Your dose will depend on your body weight, which should be measured the week before you receive 
your first dose. If you have moderate or severe kidney problems, your doctor will reduce the dose. </p>
<p>How is Plerixafor Accord given? 
Plerixafor Accord is given by subcutaneous injection (under your skin). </p>
<p>When is Plerixafor Accord given for the first time? 
You will receive your first dose 6 to 11 hours before apheresis (collection of your blood stem cells). </p>
<p>How long will Plerixafor Accord be given? 
Treatment lasts 2 to 4 consecutive days (in some cases up to 7 days), until enough stem cells have 
been collected for your transplant. In a few cases, enough stem cells may not be collected, and the 
collection attempt will be stopped. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>Please tell your doctor immediately if 
- shortly after receiving plerixafor, you experience rash, swelling around the eyes, shortness of 
breath or lack of oxygen, feeling lightheaded on standing or sitting, feeling faint or fainting 
- you have pain in the upper left abdomen (belly) or your left shoulder </p>
<p>Very common side effects (may affect more than 1 in 10 people) 
- diarrhoea, nausea (feeling sick), injection site redness or irritation 
- low red blood cell count by laboratory test (anaemia in children) </p>
<p>Common side effects (may affect up to 1 in 10 people) 
- headache 
- dizziness, feeling tired or unwell 
- difficulty in sleeping 
- flatulence, constipation, indigestion, vomiting 
- stomach symptoms such as pain, swelling or discomfort 
- dry mouth, numbness around the mouth 
- sweating, generalised redness of the skin, joint pains, pains in muscles and bones </p>
<p>Uncommon side effects (may affect up to 1 in 100 people) 
- allergic reactions such as skin rash, swelling around the eyes, shortness of breath 
- anaphylactic reactions, including anaphylactic shock 
- abnormal dreams, nightmares </p>
<p>Rarely, gastrointestinal side effects may be severe (diarrhoea, vomiting, stomach pain and nausea). </p>
<p>Heart attacks 
In clinical trials, patients with risk factors for a heart attack uncommonly suffered heart attacks after 
being given Plerixafor Accord and G-CSF. Please inform your doctor immediately if you experience 
chest discomfort. </p>
<p>Pins and needles and numbness 
Pins and needles and numbness are common in patients being treated for cancers. About one in five 
patients suffered from these feelings. However, these effects do not seem to occur more frequently 
when you use Plerixafor Accord. 
You may also have an increase in white blood cells count (leucocytosis), in your blood tests. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. 
By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store plerixafor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store plerixafor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.  </p>
<p>Do not use this medicine after the expiry date stated on the label after  EXP . The expiry date refers to 
the last day of that month.  </p>
<p>This medicine does not require any special storage conditions  </p>
<p>After opening the vial, Plerixafor Accord should be used immediately.  </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Plerixafor Accord contains 
- The active substance is plerixafor. Each ml solution for injection contains 20 mg plerixafor. 
Each vial contains 24 mg plerixafor in 1.2 ml solution. 
- The other ingredients are sodium chloride, hydrochloric acid (concentrated) and sodium 
hydroxide and water for injections (see section 2  Plerixafor Accord contains sodium ). </p>
<p>What Plerixafor Accord looks like and contents of the pack<br />
Plerixafor Accord is supplied as a clear colourless or pale yellow solution for injection in a glass vial 
with a rubber stopper, aluminium flip-off seal and PP plastic blue mate top. Each vial contains 1.2 ml 
solution. </p>
<p>Each pack contains 1 vial. </p>
<p>Marketing Authorisation Holder  </p>
<p>Accord Healthcare S.L.U.<br />
World Trade Center, Moll de Barcelona, s/n,<br />
Edifici Est 6  planta,<br />
08039 Barcelona,<br />
Spain </p>
<p>Manufacturer 
Accord Healthcare Polska Sp.z o.o. 
ul. Lutomierska 50, 
95-200 Pabianice, Poland </p>
<p>Or 
Laboratori Fundaci  Dau 
C/ C, 12-14 Pol. Ind. 
Zona Franca, Barcelona, 08040, 
Spain </p>
<p>Or 
Accord Healthcare B.V. 
Winthontlaan 200, 3526KV Utrecht 
The Netherlands </p>
<p>Or 
Pharmadox Healthcare Limited 
KW20A Kordin Industrial Park, Paola 
PLA 3000, Malta </p>
<p>This leaflet was last revised in  </p>         </div>"""      



Instance: composition-da-aefacad9a6795a89d3df82b1bc20e9aa
InstanceOf: CompositionUvEpi
Title: "Composition for plerixafor Package Leaflet"
Description:  "Composition for plerixafor Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpac7a0eeae12e9d2b6aed180d539c6255)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - plerixafor"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at få Plerixafor Accord 
3. Sådan får du Plerixafor Accord 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What plerixafor is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What plerixafor is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Plerixafor Accord indeholder det aktive stof plerixafor, der blokerer for et protein på overfladen af 
blodstamceller. Dette protein binder blodstamcellerne til knoglemarven. Plerixafor forbedrer 
frigivelsen af stamceller ud i blodbanen (mobilisering). Stamcellerne kan indsamles ved hjælp af en 
maskine, der adskiller blodets indholdsstoffer (aferese-maskine), og derefter nedfryses og opbevares 
indtil transplantationen. </p>
<p>Hvis det er vanskeligt at mobilisere, anvendes Plerixafor Accord til at hjælpe med at opsamle 
blodstamceller fra patienten med henblik på indsamling, opbevaring og genindførelse 
(transplantation), 
− 
hos voksne, der har lymfom (kræft i de hvide blodlegemer) eller myelomatose (en kræftform, 
som påvirker plasmacellerne i knoglemarven). 
− 
hos børn i alderen 1år til under 18 år, der har lymfom eller faste tumorer. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take plerixafor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take plerixafor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få Plerixafor Accord 
− 
hvis du er allergisk over for plerixafor eller et af de øvrige indholdsstoffer i Plerixafor Accord 
(angivet i punkt 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du får Plerixafor Accord. </p>
<p>Kontakt lægen: 
− 
hvis du har eller har haft hjerteproblemer. 
− 
hvis du har nyreproblemer. Lægen vil muligvis justere din dosis. 
− 
hvis du har et højt antal hvide blodlegemer. 
− 
hvis du har et lavt antal blodplader. 
− 
hvis du tidligere har haft en følelse af at skulle besvime, eller du er blevet svimmel, når du rejser 
dig op eller sætter dig op, eller du er besvimet i forbindelse med en indsprøjtning. </p>
<p>Din læge vil muligvis tage regelmæssige blodprøver for at kontrollere dit blodcelletal. </p>
<p>Det frarådes at bruge Plerixafor Accord til mobilisering af stamceller, hvis du har leukæmi (kræft i 
blodet eller knoglemarven). </p>
<p>Brug af anden medicin sammen med Plerixafor Accord 
Fortæl altid lægen eller apotekspersonalet, hvis du bruger anden medicin, for nylig har brugt anden 
medicin eller planlægger at bruge anden medicin.  </p>
<p>Graviditet og amning 
Du må ikke få Plerixafor Accord, hvis du er gravid, da der ikke er nogen erfaring med anvendelse af 
Plerixafor Accord til gravide. Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller 
planlægger at blive gravid, skal du spørge din læge til råds, før du får dette lægemiddel. Det anbefales 
at anvende prævention, hvis du er i den fødedygtige alder. </p>
<p>Du må ikke amme, hvis du får Plerixafor Accord, da det ikke vides, om Plerixafor Accord udskilles i 
modermælken. </p>
<p>Trafik- og arbejdssikkerhed 
Plerixafor Accord kan forårsage svimmelhed og træthed. Du må derfor ikke føre motorkøretøj eller 
betjene maskiner, hvis du føler dig svimmel, træt eller utilpas. </p>
<p>Plerixafor Accord indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. dosis, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take plerixafor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take plerixafor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lægemidlet vil blive indsprøjtet af en læge eller sygeplejerske. </p>
<p>Du begynder med at få G-CSF og derefter Plerixafor Accord 
Behandlingen (mobiliseringen) begynder med, at du først får et andet lægemiddel, der kaldes for G-
CSF (granulocytkoloni-stimulerende faktor). G-CSF hjælper Plerixafor Accord med at virke rigtigt i 
din krop. Hvis du vil vide mere om G-CSF, så spørg lægen og læs den tilhørende indlægsseddel. </p>
<p>Hvor meget Plerixafor Accord skal du have? 
Den anbefalede dosis til voksne er enten en 20 mg (fast dosis) eller 0,24 mg pr.kg kropsvægt pr. dag. 
Den anbefalede dosis til børn i alderen 1 år til under 18 år er 0,24 mg pr.kg kropsvægt pr. dag. </p>
<p>Din dosis afhænger af din kropsvægt, som skal måles, i ugen før du får din første dosis. Din læge vil 
nedsætte dosis, hvis du har moderate eller alvorlige nyreproblemer. </p>
<p>Hvordan gives Plerixafor Accord? 
Plerixafor Accord gives med en indsprøjtning under huden (subkutan injektion). </p>
<p>Hvornår gives Plerixafor Accord første gang? 
Du får din første dosis 6 til 11 timer inden opsamling af dine blodstamceller (aferesen). </p>
<p>Hvor lang tid gives Plerixafor Accord? 
Behandlingen varer 2 til 4 dage i træk (i nogle tilfælde op til 7 dage), indtil der er indsamlet nok 
stamceller til din transplantation. I nogle få tilfælde kan der muligvis ikke indsamles nok stamceller, 
og forsøget på at indsamle dem vil ophøre. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Fortæl det straks til lægen,<br />
− 
hvis du kort tid efter at have fået plerixafor  får udslæt, hævelse omkring øjnene, bliver 
stakåndet eller får mangel på ilt, føler dig ør, når du rejser dig op eller sætter dig ned, eller føler, 
at du skal besvime, eller du besvimer. 
− 
hvis du får smerter i øverste venstre del af maven eller i din venstre skulder. </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 patienter) 
− 
diarré, kvalme, rødmen eller irritation på injektionsstedet 
− 
lavt antal røde blodlegemer påvist i laboratorieprøve (anæmi/blodmangel hos børn) </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter) 
− 
hovedpine 
− 
svimmelhed, træthed eller utilpashed 
− 
søvnbesvær 
− 
luft i maven, forstoppelse, fordøjelsesbesvær, opkastning 
− 
symptomer i maven såsom smerter, hævelse eller ubehag 
− 
mundtørhed, følelsesløshed omkring munden 
− 
øget svedtendens, rødme i huden der breder sig, ledsmerter, smerter i muskler og knogler </p>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 patienter) 
− 
allergiske reaktioner såsom udslæt i huden, hævelse omkring øjnene, stakåndethed 
− 
anafylaktiske reaktioner, herunder anafylaktisk chok 
− 
unormale drømme, mareridt </p>
<p>Bivirkninger i mave-tarm-kanalen kan i sjældne tilfælde være alvorlige (diarré, opkastning, 
mavesmerter og kvalme). </p>
<p>Hjerteanfald 
Hjerteanfald efter at have fået Plerixafor Accord og G-CSF var en ikke almindelig bivirkning i 
kliniske forsøg hos patienter med risiko for hjerteanfald. Kontakt straks lægen, hvis du mærker ubehag 
i brystet. </p>
<p>Snurren og prikken samt følelsesløshed 
Snurren og prikken samt følelsesløshed er en almindelig bivirkning hos patienter i kræftbehandling. 
Cirka én ud af fem patienter lider af dette. Disse bivirkninger synes dog ikke at forkomme hyppigere 
ved brug af Plerixafor Accord. 
Du kan også have et øget antal hvide blodlegemer (leukocytose) i dine blodprøver. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge. Dette gælder også mulige bivirkninger, som 
ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette bivirkninger 
direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. Ved at 
indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette 
lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store plerixafor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store plerixafor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar dette lægemiddel utilgængeligt for børn. </p>
<p>Brug ikke dette lægemiddel efter den udløbsdato, der står på etiketten efter EXP. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Plerixafor Accord skal anvendes umiddelbart efter åbning af hætteglasset. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Plerixafor Accord indeholder: </p>
<p>− 
Aktivt stof: plerixafor. Hver ml injektionsvæske, opløsning, indeholder 20 mg plerixafor. Hvert 
hætteglas indeholder 24 mg plerixafor i 1,2 ml opløsning. 
− 
Øvrige indholdsstoffer: natriumchlorid, saltsyre (koncentreret), natriumhydroxid og vand til 
injektionsvæsker (se punkt 2 Plerixafor Accord indeholder natrium). </p>
<p>Udseende og pakningsstørrelser 
Plerixafor Accord leveres som en klar, farveløs eller bleggul injektionsvæske, opløsning, i et hætteglas 
med en gummiprop, flip-off-forsegling af aluminium og blå, mat hætte af PP-plast. Hvert hætteglas 
indeholder 1,2 ml opløsning. </p>
<p>Hver pakning indeholder 1 hætteglas. </p>
<p>Indehaver af markedsføringstilladelsen 
Accord Healthcare S.L.U.<br />
World Trade Center, Moll de Barcelona, s/n,<br />
Edifici Est 6ª planta,<br />
08039 Barcelona,<br />
Spanien  </p>
<p>Fremstiller 
Accord Healthcare Polska Sp.z o.o. 
ul. Lutomierska 50, 
95-200 Pabianice,<br />
Polen </p>
<p>eller 
Laboratori Fundació Dau 
C/ C, 12-14 Pol. Ind. 
Zona Franca, Barcelona, 08040, 
Spanien </p>
<p>eller 
Accord Healthcare B.V. 
Winthontlaan 200, 3526KV Utrecht 
Holland </p>
<p>eller 
Pharmadox Healthcare Limited 
KW20A Kordin Industrial Park, Paola 
PLA 3000,<br />
Malta </p>
<p>Hvis du ønsker yderligere oplysninger om Plerixafor Accord, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>AT / BE / BG / CY / CZ / DE / DK / EE / FI / FR / HR / HU / IE / IS / IT / LT / LV / LX / MT / NL / </p>
<p>NO / PT / PL / RO / SE / SI / SK / UK(NI) / ES 
Accord Healthcare S.L.U. 
Tel: +34 93 301 00<br />
EL 
Win Medica Pharmaceutical S.A.<br />
Tel: +30 210 7488  </p>
<p>Denne indlægsseddel blev senest ændret </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-aefacad9a6795a89d3df82b1bc20e9aa
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for plerixafor Package Leaflet for language en"
Description: "ePI document Bundle for plerixafor Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-aefacad9a6795a89d3df82b1bc20e9aa"
* entry[0].resource = composition-en-aefacad9a6795a89d3df82b1bc20e9aa

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpaefacad9a6795a89d3df82b1bc20e9aa"
* entry[=].resource = mpaefacad9a6795a89d3df82b1bc20e9aa
                            
                    
Instance: bundlepackageleaflet-da-aefacad9a6795a89d3df82b1bc20e9aa
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for plerixafor Package Leaflet for language da"
Description: "ePI document Bundle for plerixafor Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-aefacad9a6795a89d3df82b1bc20e9aa"
* entry[0].resource = composition-da-aefacad9a6795a89d3df82b1bc20e9aa

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpaefacad9a6795a89d3df82b1bc20e9aa"
* entry[=].resource = mpaefacad9a6795a89d3df82b1bc20e9aa
                            
                    



Instance: mpaefacad9a6795a89d3df82b1bc20e9aa
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Plerixafor Accord 20 mg/ml solution for injection"
Description: "Plerixafor Accord 20 mg/ml solution for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/22/1701/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Plerixafor Accord 20 mg/ml solution for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: aefacad9a6795a89d3df82b1bc20e9aaListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "plerixafor"

* status = #current
* mode = #working

* title = "List of all ePIs associated with plerixafor"

* subject = Reference(mpac7a0eeae12e9d2b6aed180d539c6255)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#plerixafor "plerixafor"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-aefacad9a6795a89d3df82b1bc20e9aa) // plerixafor en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-aefacad9a6795a89d3df82b1bc20e9aa) // plerixafor da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-aefacad9a6795a89d3df82b1bc20e9aa
InstanceOf: List

* insert aefacad9a6795a89d3df82b1bc20e9aaListRuleset
    